United Therapeutics (UTHR) Interest & Investment Income (2009 - 2026)

United Therapeutics has disclosed Interest & Investment Income across 16 years of filings, most recently posting $41.8 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $41.8 million, down 18.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $182.7 million (down 6.98% YoY), and the FY2025 annual result was $192.0 million, down 3.57% from the prior year.
• Interest & Investment Income came in at $41.8 million for Q1 2026 at United Therapeutics, down from $43.2 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $53.8 million in Q1 2024 to a low of $4.3 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $45.3 million (2023), against an average of $37.7 million.
• Across the five-year window, Interest & Investment Income soared 579.07% in 2023 and retreated 18.2% in 2026, its largest moves.
• United Therapeutics' Interest & Investment Income stood at $20.8 million in 2022, then surged by 145.19% to $51.0 million in 2023, then dropped by 3.33% to $49.3 million in 2024, then decreased by 12.37% to $43.2 million in 2025, then decreased by 3.24% to $41.8 million in 2026.
• The last three Interest & Investment Income figures came in at $41.8 million (Q1 2026), $43.2 million (Q4 2025), and $46.4 million (Q3 2025), per Business Quant data.